BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15205214)

  • 1. Irinotecan chemotherapy associated with transient dysarthria and aphasia.
    De Marco S; Squilloni E; Vigna L; Bertagnolio MF; Sternberg CN
    Ann Oncol; 2004 Jul; 15(7):1147-8. PubMed ID: 15205214
    [No Abstract]   [Full Text] [Related]  

  • 2. Irinotecan-induced dysarthria.
    Baz DV; Bofill JS; Nogueira JA
    J Natl Cancer Inst; 2001 Sep; 93(18):1419-20. PubMed ID: 11562394
    [No Abstract]   [Full Text] [Related]  

  • 3. [Dysarthria during irinotecan administration].
    Ceccaldi B; Kara F; Mommeja-Marin H; Bègue M; Saint Blancard P; Le Marec E; Hauteville D
    Rev Med Interne; 2002 Nov; 23(11):950-1. PubMed ID: 12481397
    [No Abstract]   [Full Text] [Related]  

  • 4. [A case of sigmoid colon cancer with temporary dysarthria associated with irinotecan].
    Sogabe S; Yuki S; Takano H; Kobayashi Y; Nakatsumi H; Sasaki T; Kawamoto Y; Fukushima H; Iwanaga I; Uehata Y; Komatsu Y; Asaka M
    Gan To Kagaku Ryoho; 2011 Aug; 38(8):1375-7. PubMed ID: 21829085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irinotecan-induced immune thrombocytopenia.
    Mirtsching BC; George JN; Aster RH; Curtis BR
    Am J Med Sci; 2014 Feb; 347(2):167-9. PubMed ID: 24472819
    [No Abstract]   [Full Text] [Related]  

  • 6. [Application and recent research progress of irinotecan in treatment of advanced colorectal cancer].
    Guan ZZ
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):718-9. PubMed ID: 17274384
    [No Abstract]   [Full Text] [Related]  

  • 7. Dysarthria induced by irinotecan in a patient with colorectal cancer.
    Lee KA; Kang HW; Ahn JH; Suk HJ; Kim H
    Am J Health Syst Pharm; 2013 Jul; 70(13):1140-3. PubMed ID: 23784161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intergroup trial fails to demonstrate a benefit with the addition of irinotecan to bolus 5-fluorouracil/leucovorin in stage III colon cancer.
    Reddy GK
    Clin Colorectal Cancer; 2004 Nov; 4(4):230-2. PubMed ID: 15555203
    [No Abstract]   [Full Text] [Related]  

  • 9. Irinotecan/5-fluorouracil/leucovorin in advanced colorectal cancer: Oncologic Drugs Advisory committee summary.
    Oncologic Drugs Advisory Committee
    Clin Colorectal Cancer; 2002 May; 2(1):8-10. PubMed ID: 12453328
    [No Abstract]   [Full Text] [Related]  

  • 10. Neomycin as secondary prophylaxis for irinotecan-induced diarrhea.
    Schmittel A; Jahnke K; Thiel E; Keilholz U
    Ann Oncol; 2004 Aug; 15(8):1296. PubMed ID: 15277273
    [No Abstract]   [Full Text] [Related]  

  • 11. [Standard chemotherapy for colonic neoplasms].
    Hyodo I
    Nihon Naika Gakkai Zasshi; 2007 Feb; 96(2):283-8. PubMed ID: 17370594
    [No Abstract]   [Full Text] [Related]  

  • 12. Irinotecan in the adjuvant treatment of colon cancer: is the story finished or does personalized therapy open new opportunities?
    Gasparini G; D'Andrea MR; Toffoli G
    J Clin Oncol; 2010 Apr; 28(12):e199. PubMed ID: 20308659
    [No Abstract]   [Full Text] [Related]  

  • 13. Irinotecan and UFT/leucovorin in patients with advanced cancers.
    Stevenson JP; Redlinger M; Sun W; Haller D; O'Dwyer PJ
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):91-2. PubMed ID: 11098504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irinotecan-induced immune thrombocytopenia.
    Bozec L; Bierling P; Fromont P; Lévi F; Debat P; Cvitkovic E; Misset JL
    Ann Oncol; 1998 Apr; 9(4):453-5. PubMed ID: 9636839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moving beyond fluorouracil for colorectal cancer.
    Mayer RJ
    N Engl J Med; 2000 Sep; 343(13):963-4. PubMed ID: 11006373
    [No Abstract]   [Full Text] [Related]  

  • 16. [CPT-11: new drug for metastatic colorectal cancer].
    Barone C; Pozzo C; Cassano A
    Tumori; 1999; 85(6):A1-11. PubMed ID: 10774581
    [No Abstract]   [Full Text] [Related]  

  • 17. Dual deficiency of DPD and UGT1A1 in a case of colon cancer.
    Rawlley B; Diab O; Al-Rajabi R; Carroll E; Melancon T; Kasi A
    Pharmacogenomics; 2020 Dec; 21(18):1265-1269. PubMed ID: 33203301
    [No Abstract]   [Full Text] [Related]  

  • 18. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.
    Fujita K; Kubota Y; Ishida H; Sasaki Y
    World J Gastroenterol; 2015 Nov; 21(43):12234-48. PubMed ID: 26604633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and ongoing trials with irinotecan in the United States.
    Fuchs CS
    Semin Oncol; 2003 Aug; 30(4 Suppl 12):9-17. PubMed ID: 14508722
    [No Abstract]   [Full Text] [Related]  

  • 20. Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.
    Falcone A; Di Paolo A; Masi G; Allegrini G; Danesi R; Lencioni M; Pfanner E; Comis S; Del Tacca M; Conte P
    J Clin Oncol; 2001 Aug; 19(15):3456-62. PubMed ID: 11481350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.